Cargando…

Listeria monocytogenes as a Vector for Cancer Immunotherapy

Cancer is a wide group of diseases, which was responsible for 9.6 million deaths in 2018. Cancer immunotherapies have become a reality, with the first approval for sipuleucel-T for prostate cancer therapy occurring in 2010. Listeria monocytogenes is a Gram-positive bacterium, mostly known as a food-...

Descripción completa

Detalles Bibliográficos
Autor principal: Leitão, Jorge H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563333/
https://www.ncbi.nlm.nih.gov/pubmed/32764358
http://dx.doi.org/10.3390/vaccines8030439
_version_ 1783595466737319936
author Leitão, Jorge H.
author_facet Leitão, Jorge H.
author_sort Leitão, Jorge H.
collection PubMed
description Cancer is a wide group of diseases, which was responsible for 9.6 million deaths in 2018. Cancer immunotherapies have become a reality, with the first approval for sipuleucel-T for prostate cancer therapy occurring in 2010. Listeria monocytogenes is a Gram-positive bacterium, mostly known as a food-borne pathogen, capable of causing life-threatening and often fatal infections. However, since in the majority of cases the human immune system is able to mount potent innate and adaptive immune responses that control infections by Listeria monocytogenes, the microorganism has become an attractive vector for the development of cancer vaccines. The review by Flickinger Jr., Rodeck and Snook (Vaccines 2018, 6, 48) on the use of Listeria monocytogenes as a vector for cancer immunotherapy is described and commented here.
format Online
Article
Text
id pubmed-7563333
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75633332020-10-27 Listeria monocytogenes as a Vector for Cancer Immunotherapy Leitão, Jorge H. Vaccines (Basel) Editorial Cancer is a wide group of diseases, which was responsible for 9.6 million deaths in 2018. Cancer immunotherapies have become a reality, with the first approval for sipuleucel-T for prostate cancer therapy occurring in 2010. Listeria monocytogenes is a Gram-positive bacterium, mostly known as a food-borne pathogen, capable of causing life-threatening and often fatal infections. However, since in the majority of cases the human immune system is able to mount potent innate and adaptive immune responses that control infections by Listeria monocytogenes, the microorganism has become an attractive vector for the development of cancer vaccines. The review by Flickinger Jr., Rodeck and Snook (Vaccines 2018, 6, 48) on the use of Listeria monocytogenes as a vector for cancer immunotherapy is described and commented here. MDPI 2020-08-05 /pmc/articles/PMC7563333/ /pubmed/32764358 http://dx.doi.org/10.3390/vaccines8030439 Text en © 2020 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Editorial
Leitão, Jorge H.
Listeria monocytogenes as a Vector for Cancer Immunotherapy
title Listeria monocytogenes as a Vector for Cancer Immunotherapy
title_full Listeria monocytogenes as a Vector for Cancer Immunotherapy
title_fullStr Listeria monocytogenes as a Vector for Cancer Immunotherapy
title_full_unstemmed Listeria monocytogenes as a Vector for Cancer Immunotherapy
title_short Listeria monocytogenes as a Vector for Cancer Immunotherapy
title_sort listeria monocytogenes as a vector for cancer immunotherapy
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563333/
https://www.ncbi.nlm.nih.gov/pubmed/32764358
http://dx.doi.org/10.3390/vaccines8030439
work_keys_str_mv AT leitaojorgeh listeriamonocytogenesasavectorforcancerimmunotherapy